Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

Delivery systems for siRNA drug development in cancer therapy
Publication date: Available online 28 August 2014 Source:Asian Journal of Pharmaceutical Sciences Author(s): Cong-fei Xu , Jun Wang Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten years ago, it has become a promising drug target for the treatment of multiple diseases, including cancer. There have already been some successful applications of siRNA drugs in the treatment of age-related macular degeneration and respiratory syncytial virus infection. However, significant barriers still exist on the road to clinical applications of siRNA drugs, including poor cellular uptake, instabilit...
Source: Asian Journal of Pharmaceutical Sciences - October 12, 2014 Category: Drugs & Pharmacology Source Type: research

Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in-vitro analysis.
Abstract In man brain cancer is an aggressive, malignant form of tumor, it is highly infiltrative in nature, is associated with cellular heterogeneity and affects cerebral hemispheres of the brain. Current drug therapies are inadequate and an unmet clinical need exists to develop new improved therapeutics. The ability to silence genes associated with disease progression by using short interfering RNA (siRNA) presents the potential to develop safe and effective therapies. In this work, in order to protect the siRNA from degradation, promote cell specific uptake and enhance gene silencing efficiency, a PEGylated cyc...
Source: European Journal of Pharmaceutical Sciences - February 19, 2015 Category: Drugs & Pharmacology Authors: Gooding M, Malhotra M, McCarthy DJ, Godinho BM, Cryan JF, Darcy R, O'Driscoll CM Tags: Eur J Pharm Sci Source Type: research

Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders.
This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers. PMID: 26471319 [PubMed - in process]
Source: Current Pharmaceutical Design - October 18, 2015 Category: Drugs & Pharmacology Authors: Maheshwari R, Tekade M, Sharma PA, Tekade RK Tags: Curr Pharm Des Source Type: research

siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector.
Abstract siRNA technology presents a helpful means of gene silencing in mammalian cells. Advancement in the field includes enhanced attentiveness in the characterization of target and off-target effects employing suitable controls and gene expression microarrays. These will permit expansion in the measurement of single and multiple target combinations and also permit comprehensive efforts to understand mammalian cell processes. Another fact is that the delivery of siRNA requires the creation of a nanoparticulate vector with controlled structural geometry and surface modalities inside the targeted cells. On the oth...
Source: Current Pharmaceutical Design - October 23, 2015 Category: Drugs & Pharmacology Authors: Tekade RK, Maheshwari RG, Sharma PA, Tekade M, Chauhan AS Tags: Curr Pharm Des Source Type: research

Nanoplatforms for Delivery of siRNA to the Eye.
Abstract Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show g...
Source: Current Pharmaceutical Design - October 23, 2015 Category: Drugs & Pharmacology Authors: Kataki MS, Kakoti BB, Jameson M, Solanki A, Hirani A, Pathak Y Tags: Curr Pharm Des Source Type: research

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
In this study we aim to develop pegylated siRNA lipoplexes formed using the cationic lipid DOTAP and DSPE-PEG2000, capable to effectively stabilize anti Blimp-1 siRNA and suitable for systemic administration. Two types of pegylated lipoplexes using a classic (C-PEG Lipoplexes) or a post-pegylation method (P-PEG-Lipoplexes) were formulated and compared in their physicochemical properties (size, zeta potential, morphology and structure) and efficiency on PEL cell lines. A stable siRNAs protection was obtained with post pegylation approach (2% molar of DSPE-PEG2000 respect to lipid) resulting in structures with diameters of 3...
Source: European Journal of Pharmaceutics and Biopharmaceutics - November 25, 2015 Category: Drugs & Pharmacology Authors: Belletti D, Tosi G, Forni F, Lagreca I, Barozzi P, Pederzoli F, Vandelli MA, Riva G, Luppi M, Ruozi B Tags: Eur J Pharm Biopharm Source Type: research

Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells
Conclusion The siRNA-induced AKT3 and PI3KCA mRNA knockdown in combination with TMZ and BCNU inhibited proliferation and induced apoptosis and autophagy in T98G cells. Thus, knockdown of these genes in combination with TMZ and BCNU may offer a novel therapeutic strategy to more effectively control the growth of human GBM cells, but further studies are necessary to confirm a positive phenomenon for the treatment of GBM.
Source: BioDrugs - February 22, 2016 Category: Drugs & Pharmacology Source Type: research

Delivery strategies and potential targets for siRNA in major cancer types.
Abstract Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, var...
Source: Advanced Drug Delivery Reviews - May 30, 2016 Category: Drugs & Pharmacology Authors: Lee SJ, Kim MJ, Kwon IC, Roberts TM Tags: Adv Drug Deliv Rev Source Type: research

Smart inulin-based polycationic nanodevices for siRNA delivery.
Abstract The advances of short interfering RNA (siRNA) mediated therapy provide a powerful option for treatment of many diseases by silencing the expression of targeted genes including cancer development and progression. Inulin is a very simple and biocompatible polysaccharide proposed by our groups to produce interesting delivery systems for Nucleic acid based drugs (NABDs), such as siRNA, either as polycations able to give polyplexes and polymeric coatings for nanosystems having a metallic core. In this research field different functionalizing groups were linked to the inulin backbone with specific aims includin...
Source: Current Drug Delivery - August 10, 2016 Category: Drugs & Pharmacology Authors: Lamberti G, Cavallaro G, Sardo C, Scialabba C, Licciardi M, Giammona G Tags: Curr Drug Deliv Source Type: research

Overcoming the challenges of siRNA delivery: Nanoparticle strategies.
Abstract RNA interference (RNAi) is a natural cellular process that can be operated to silence specific genes expression in post-transcriptional level by intracellular delivery of small interfering RNAs (siRNAs) and microRNAs. Therapeutics based on siRNA have an immense potential for the treatment of incurable diseases such as cancers. However, the in vivo utilization of siRNA and also the delivery of this agent to the target site is one of the most controversial challenges, the helpful assistance by nanoparticles can improve stable delivery and also enhance efficacy. More nanoparticle-based siRNA therapeutics is ...
Source: Current Drug Delivery - August 15, 2016 Category: Drugs & Pharmacology Authors: Shajari N, Mansoori B, Davudian S, Mohammadi A, Baradaran B Tags: Curr Drug Deliv Source Type: research

Cell Type-Specific Responses of Peripheral Blood CD14-Positive Monocytes to Liposome-Encapsulated Immunostimulatory siRNA.
Abstract RNA interference via small interfering RNA (siRNA) has many potential therapeutic applications, and liposomal-based systems are useful for improving the pharmacokinetics of siRNAs, including their intracellular release and distribution. However, for the successful translation of this technology into clinical applications, it is important to understand how liposomal encapsulation changes the cellular uptake and immunostimulatory adverse effects of siRNAs. Here we evaluated the cellular uptake and innate immune activation by an immunostimulatory siRNA encapsulated within a liposome carrier in commercially a...
Source: Biological and Pharmaceutical Bulletin - November 4, 2016 Category: Drugs & Pharmacology Authors: Abe Y, Sakai-Kato K, Goda Y Tags: Biol Pharm Bull Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line.
CONCLUSION: Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy. PMID: 28092843 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 12, 2017 Category: Drugs & Pharmacology Authors: Aletaha M, Mansoori B, Mohammadi A, Fazeli M, Baradaran B Tags: Biomed Pharmacother Source Type: research

Enhanced cellular uptake and gene silencing activity of siRNA using temperature-responsive polymer-modified liposome
In this study, to develop the temperature-responsive liposome as a novel carrier for siRNA delivery, we prepared lipoplexes and assessed cellular uptake of siRNA and gene silencing activity of target genes, compared with those of a commercial transfection reagent, Lipofectamine RNAiMAX, and non-modified or PEGylated liposomes. The temperature-responsive polymer, N-isopropylacrylamide-co-N,N’-dimethylaminopropylacrylamide [P(NIPAAm-co-DMAPAAm)]-modified liposome induced faster intracellular delivery because P(NIPAAm-co-DMAPAAm) exhibits a lower critical solution temperature (LCST) changing its nature from hydrophilic to h...
Source: International Journal of Pharmaceutics - March 28, 2017 Category: Drugs & Pharmacology Source Type: research

Influence of controlled release of resveratrol from electrospun fibers in combination with siRNA on leukemia cells.
In this study, we evaluated the possibility of i) local release of resveratrol from poly(ε-caprolactone) (PCL) and gelatin (GT) electrospun fibers and ii) combining (i) with siRNA designed to downregulate BCR-ABL pathway on K562 cancer cells. Initially, K562 cell culture experiments were performed using various bolus doses of resveratrol in combination with siRNA for 3 days using a factorial design of experiments approach. Resveratrol content was analyzed using HPLC and cell viability was assessed using Annexin V (Non-viable), and Propidium Iodide (PI) (Necrotic) based flow cytometry. Coaxial electrospun fibers with res...
Source: European Journal of Pharmaceutical Sciences - July 21, 2018 Category: Drugs & Pharmacology Authors: Al-Attar T, Madihally SV Tags: Eur J Pharm Sci Source Type: research

Nanostructured Hyaluronic acid-based materials for the delivery of siRNA.
CONCLUSION: To overcome the problems associated with these emerging genetic tools, investigators have employed glycosaminoglycan HA-based biopolymers. This biopolymer offers a variety of properties such as biodegradability, biocompatibility, aqueous solubility, viscoelasticity, and non-immunogenicity. PMID: 30084325 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Shah K, Chawla S, Agrawal A, Reddy G, Maheshwari R, Kalia K, Tekade RK Tags: Curr Pharm Des Source Type: research